ENSMUSG00000056133 Activators
UNC-93 homolog A2 activators encompass a diverse class of chemical compounds that influence various aspects of cellular trafficking and signaling, leading to the enhanced functional activity of UNC-93 homolog A2. Bafilomycin A1, U18666A, and Chloroquine, for instance, modulate the endolysosomal pH and cholesterol content, thereby impacting the trafficking and degradation pathways crucial for UNC-93 homolog A2 function. By disrupting normal lysosomal acidification and cholesterol transport, these compounds indirectly cause an accumulation of endosomal substrates, which could result in the increased activity of UNC-93 homolog A2 as it is forced to accommodate and process the heightened vesicular load. Similarly, Monensin, by altering sodium gradients, and ML9, through its influence on the cytoskeleton, perturb the vesicular trafficking process. This results in a subsequent impact on the functional role of UNC-93 homolog A2, which is intrinsically associated with vesicular transport in the cell.
Furthermore, compounds such as PMA, which activates PKC, and Nicardipine, a calcium channel blocker, fine-tune the signaling cascades and ion homeostasis that UNC-93 homolog A2 relies upon for its vesicular trafficking function. The activation of PKC by PMA can potentiate the vesicular fusion or release events, directly impacting the involvement of UNC-93 homolog A2 in these processes. Nicardipine's modulation of calcium influx can similarly influence calcium-dependent trafficking mechanisms, thereby enhancing the function of UNC-93 homolog A2. Nocodazole and Wortmannin, by disrupting microtubule dynamics and inhibiting PI3K respectively, create an altered intracellular environment that can lead to the enhanced activity of UNC-93 homolog A2 by affecting vesicle positioning and endosomal sorting. Compounds like Dynasore and FM1-43, which interfere with dynamin function and vesicle trafficking, along with Methyl-β-cyclodextrin, which affects membrane fluidity and curvature, also contribute to the activation of UNC-93 homolog A2 by changing the vesicular landscape, thereby facilitating an environment that necessitates the heightened function of UNC-93 homolog A2.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $96.00 $250.00 $750.00 $1428.00 | 280 | |
Bafilomycin A1 is a specific inhibitor of the vacuolar-type H+-ATPase. By inhibiting this pump, it leads to an increase in lysosomal pH, which can affect the lysosomal degradation process. UNC-93 homolog A2 is associated with endolysosomal trafficking; thus, the inhibition of lysosomal acidification can lead to altered trafficking and potentially enhanced activity of UNC-93 homolog A2 due to accumulation of endosomal substrates. | ||||||
U 18666A | 3039-71-2 | sc-203306 sc-203306A | 10 mg 50 mg | $140.00 $500.00 | 2 | |
U18666A is a cholesterol transport inhibitor which induces the accumulation of unesterified cholesterol in late endosomes and lysosomes. This accumulation can affect membrane trafficking and may promote the functional activity of UNC-93 homolog A2 by altering the lipid environment and affecting its localization or stabilization within endosomal membranes. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $152.00 $515.00 | ||
Monensin is a sodium ionophore that disrupts transmembrane ion gradients. By affecting ion homeostasis, monensin can influence endolysosomal trafficking pathways, which may indirectly enhance the function of UNC-93 homolog A2 by modulating the endolysosomal compartments it associates with. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Chloroquine is a weak base known to inhibit lysosomal enzymes by increasing the pH within the lysosome. This increase in pH can alter the endolysosomal trafficking, and as UNC-93 homolog A2 is involved in this process, chloroquine can lead to enhanced activity of UNC-93 homolog A2 by impairing lysosomal degradation pathways. | ||||||
ML-9 | 105637-50-1 | sc-200519 sc-200519A sc-200519B sc-200519C | 10 mg 50 mg 100 mg 250 mg | $110.00 $440.00 $660.00 $1200.00 | 2 | |
ML9 is a kinase inhibitor that can indirectly affect cytoskeletal dynamics. Since the cytoskeleton plays a role in vesicular trafficking, ML9 can enhance the functional activity of UNC-93 homolog A2 by influencing vesicular movement and distribution, which are essential for the protein’s trafficking function. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA is a potent activator of protein kinase C (PKC) which influences various cellular processes including vesicle trafficking. By activating PKC, PMA can enhance trafficking mechanisms that UNC-93 homolog A2 is involved in, potentially increasing its activity by promoting vesicular fusion or release events. | ||||||
Nicardipine hydrochloride | 54527-84-3 | sc-202731 sc-202731A | 1 g 5 g | $32.00 $81.00 | 5 | |
Nicardipine is a calcium channel blocker that can alter calcium influx. Since calcium is a crucial secondary messenger in cellular signaling and vesicle trafficking, nicardipine can indirectly enhance the function of UNC-93 homolog A2 by affecting the calcium-dependent processes it is involved in. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $58.00 $83.00 $140.00 $242.00 | 38 | |
Nocodazole is a microtubule-depolymerizing agent which disrupts microtubule networks. As microtubules are integral for vesicle transport, nocodazole can enhance the functional activity of UNC-93 homolog A2 by altering microtubule dynamics, potentially affecting the positioning and movement of vesicles associated with UNC-93 homolog A2. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3K), which are involved in intracellular trafficking. By inhibiting PI3K, wortmannin can influence the endosomal sorting and trafficking pathways, potentially enhancing the activity of UNC-93 homolog A2 by affecting the recruitment of vesicles to the endolysosomal compartments. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $87.00 | 44 | |
Dynasore is a GTPase inhibitor that targets dynamin, preventing vesicle scission from the membrane. This can lead to altered endocytic trafficking, which may enhance the functional activity of UNC-93 homolog A2 by accumulating endocytic vesicles that require UNC-93 homolog A2 for proper processing and trafficking. | ||||||